These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37559984)

  • 1. Accelerated glycolysis in tumor microenvironment is associated with worse survival in triple-negative but not consistently with ER+/HER2- breast cancer.
    Oshi M; Roy AM; Yan L; Sasamoto M; Tokumaru Y; Wu R; Yamada A; Yamamoto S; Chishima T; Narui K; Endo I; Takabe K
    Am J Cancer Res; 2023; 13(7):3041-3054. PubMed ID: 37559984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical relevance of unfolded protein response signaling in breast cancer.
    Oshi M; Roy AM; Gandhi S; Tokumaru Y; Yan L; Yamada A; Endo I; Takabe K
    Am J Cancer Res; 2022; 12(6):2627-2640. PubMed ID: 35812054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.
    Oshi M; Gandhi S; Yan L; Tokumaru Y; Wu R; Yamada A; Matsuyama R; Endo I; Takabe K
    Breast Cancer Res Treat; 2022 Jul; 194(2):231-241. PubMed ID: 35639264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer.
    Oshi M; Gandhi S; Angarita FA; Kim TH; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    Am J Cancer Res; 2021; 11(7):3611-3627. PubMed ID: 34354863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.
    Tokumaru Y; Oshi M; Katsuta E; Yan L; Satyananda V; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
    Am J Cancer Res; 2020; 10(3):897-907. PubMed ID: 32266098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G2M checkpoint pathway alone is associated with drug response and survival among cell proliferation-related pathways in pancreatic cancer.
    Oshi M; Patel A; Le L; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    Am J Cancer Res; 2021; 11(6):3070-3084. PubMed ID: 34249445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conflicting roles of
    Oshi M; Gandhi S; Tokumaru Y; Yan L; Yamada A; Matsuyama R; Ishikawa T; Endo I; Takabe K
    Am J Cancer Res; 2021; 11(10):5094-5110. PubMed ID: 34765314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer.
    Schulze A; Oshi M; Endo I; Takabe K
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33143224
    [No Abstract]   [Full Text] [Related]  

  • 9. Enhanced Thermogenesis in Triple-Negative Breast Cancer Is Associated with Pro-Tumor Immune Microenvironment.
    Gandhi S; Oshi M; Murthy V; Repasky EA; Takabe K
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes.
    Vishnubalaji R; Alajez NM
    Cells; 2023 Apr; 12(8):. PubMed ID: 37190091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer.
    Oshi M; Takahashi H; Tokumaru Y; Yan L; Rashid OM; Matsuyama R; Endo I; Takabe K
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32331421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival.
    Oshi M; Tokumaru Y; Angarita FA; Lee L; Yan L; Matsuyama R; Endo I; Takabe K
    Sci Rep; 2021 Jun; 11(1):12541. PubMed ID: 34131208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of KAM score to predict metastasis and worse survival in breast cancer.
    McDonald KA; Oshi M; Kawaguchi T; Qi Q; Peng X; Yamada A; Opyrchal M; Liu S; Yao S; Otsuji E; Yan L; Endo I; Takabe K
    Am J Cancer Res; 2021; 11(11):5388-5401. PubMed ID: 34873467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low expression of miR-195 is associated with cell proliferation, glycolysis and poor survival in estrogen receptor (ER)-positive but not in triple negative breast cancer.
    Tokumaru Y; Oshi M; Patel A; Katsuta E; Yan L; Angarita FA; Dasgupta S; Nagahashi M; Matsuhashi N; Futamura M; Yoshida K; Takabe K
    Am J Cancer Res; 2021; 11(6):3320-3334. PubMed ID: 34249465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
    Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
    Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High miR-99b expression is associated with cell proliferation and worse patient outcomes in breast cancer.
    Oshi M; Tokumaru Y; Benesch MG; Sugito N; Wu R; Yan L; Yamada A; Chishima T; Ishikawa T; Endo I; Takabe K
    Am J Cancer Res; 2022; 12(10):4840-4852. PubMed ID: 36381329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
    Sato T; Oshi M; Huang JL; Chida K; Roy AM; Endo I; Takabe K
    Res Sq; 2024 Mar; ():. PubMed ID: 38585981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOBEC3F expression in triple-negative breast cancer is associated with tumor microenvironment infiltration and activation of cancer immunity and improved survival.
    Wu R; Oshi M; Asaoka M; Huyser MR; Tokumaru Y; Yamada A; Yan L; Endo I; Ishikawa T; Takabe K
    Am J Cancer Res; 2022; 12(2):744-762. PubMed ID: 35261799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Oshi M; Angarita FA; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
    Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
    FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.